Sarepta (SRPT) - Forward P/S Multiple

Corporate company logo of Sarepta Therapeutics (SRPT)

Sarepta Therapeutics, Inc. (SRPT) dominates muscular dystrophy therapy, leveraging exclusive patents and FDA approval to create insurmountable barriers for competitors. The forward P/S ratio visualizes market expectations, where the 0.80 mark characterizes this parameter. Innovative DNA-based drugs ensure a steady cash flow, while a closed diagnostic ecosystem guarantees absolute patient loyalty to the brand's products.

SRPT sarepta.com: Forward Price to Sales in the range 07/04/2022 - 11/18/2026

Financial and market metric breakdowns for Sarepta Therapeutics, Inc. (SRPT)

- current price and projected stock value:
Initial company analysis:Sarepta Therapeutics (SRPT)
Original product of Sarepta Corp

Forward P/S is a key tool for valuing an asset relative to its future cash flows. This metric correlates current market capitalization with projected annual sales volume, filtering out short-term market noise. By analyzing a business's forward P/S, an investor determines the extent of expectations already priced in. For Sarepta Therapeutics, Inc. (SRPT), this reflects the market's bet on the commercial success of Elevidys and the expansion potential of gene therapy.

Competitors of Sarepta Therapeutics, Inc.

Forward P/S Multiple TEM (Tempus Labs)|Qiagen N.V. - Price-to-Projected Revenue Ratio|IONS - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio repligen.com|RNA: Forward P/S Multiple|CRISPR Therapeutics Inc (CRSP) - Forward P/S Multiple|WGS (GeneDx Holdings) - Forward P/S Multiple|RARE: Forward Price to Sales|Forward Price-to-Revenue Multiple BEAM (Beam Therapeutics Corp)|Twist Bioscience - Market Cap to Projected Revenue|10x Genomics Inc - Forward Price-to-Revenue Multiple|NTLA (Intellia Therapeutics, Inc.) - Future Price to Revenue|Stoke Corp - Forward P/S Multiple|BLFS (BioLife) - Market Cap to Projected Revenue|wavelifesciences.com (WVE) - Price-to-Projected Revenue Ratio|MAZE - Market Cap to Expected Sales Ratio|SION (Sionna Therapeutics, Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Prime Medicine Corp (PRME)|Forward P/S Multiple TSHA|Forward P/S Multiple uniQure N.V. (QURE)|Price-to-Projected Revenue Ratio MeiraGTx Holdings plc MGTX|RGNX: Market Cap to Projected Revenue|Solid Biosciences Inc - Forward P/S Multiple|OCGN - Forward P/S Multiple|PACB: Forward P/S Multiple|BNTC - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Design Therapeutics, Inc.|RCKT: Forward Price to Sales|Forward Price-to-Revenue Multiple FDMT (4D Molecular Therapeutics, Inc.)|Lexeo Therapeutics, Inc. - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Korro Bio, Inc. KRRO|EDIT: Market Cap to Projected Revenue|SLN - Price-to-Projected Revenue Ratio|Projected Price to Revenue ProQR Therapeutics (PRQR)|CDXS (Codexis Bio) - Forward Price-to-Revenue Multiple|Sangamo Therapeutics Inc. (SGMO) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Nautilus Bio|Market Cap to Future Revenue Ratio Metagenomi Therapeutics MGX|Price-to-Projected Revenue Ratio Precision BioSciences (DTIL)|GBIO - Market Cap to Future Revenue Ratio|Forward P/S Multiple BOLD (Boundless Bio, Inc)|XCUR - Forward Price-to-Revenue Multiple|IMNN - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Phio Pharmaceuticals Corp|MBIO: Forward P/S Multiple|TransCode (RNAZ) - Forward P/S Multiple|BNGO (Bionano) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Applied DNA Sciences, Inc. APDN|Forward P/S Multiple BLUE|ImmunoPrecise Antibodies Ltd - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Omega Therapeutics OMGA|OMIC: Market Cap to Projected Revenue|RGLS: Forward Price-to-Revenue Multiple|Forward Price to Sales SYRS (Syros Pharmaceuticals, Inc.)|Telesis Bio, Inc. (TBIO) - Price-to-Projected Revenue Ratio|Future Price to Revenue TCON (TRACON)|Price-to-Projected Revenue Ratio Unity Biotechnology, Inc.